Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Gannan Normal Univ. RETV804M compound 11ic
- Development stage
- Unknown
- Lead developer
- Gannan Normal University
01
Overview
Gannan Normal Univ. RETV804M compound 11ic: sourced facts only. name: "One of the optimal compounds, 11ic, inhibited the proliferation of BaF3 cells harboring the CCDC6-RETV804M and CCDC6-RETG810C mutations, with IC50 values of 0.0208 μM and 0.096 μM, respectively." [PMID:42607442]; target: "One of the optimal compounds, 11ic, inhibited the proliferation of BaF3 cells harboring the CCDC6-RETV804M and CCDC6-RETG810C mutations, with IC50 values of 0.0208 μM and 0.096 μM, respectively." [PMID:42607442]; developer: "Jiangxi Provincial Key Laboratory of Synthetic Pharmaceutical Chemistry, Gannan Normal University, Ganzhou 341000, China." [PMID:42607442]
02
Targets
RET (Rearranged during transfection receptor tyrosine kinase)
Beyond the preview
Go deeper on Gannan Normal Univ. RETV804M compound 11ic.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Gannan Normal Univ. RETV804M compound 11ic.